Recursion Pharmaceuticals Accounts Payable

As of the most recent data (June 2026), RXRX shows a accounts payable of $13M. That compares with $19M in the prior-year period — down 34.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RXRX's accounts payable is now $13M (was $19M) — a 34.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Recursion Pharmaceuticals is outperforming or lagging.

Tracking RXRX's accounts payable over time shows whether Recursion Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $13M That compares with $19M in the prior-year period — down 34.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Recursion Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $13M) with ownership activity and broader fundamentals.

Recursion Pharmaceuticals's accounts payable is $13M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.